OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Commerce. All rights reserved.
Focus on operational excellence is playing a major role in this effort, company says
Piramal Pharma Solutions (PPS), a contract development and manufacturing organization (CDMO) and part of Piramal Pharma Limited, announced that the company's site in Digwal in the state of Telangana, India, has implemented various tools to unlock active pharmaceutical ingredient (API) manufacturing capacity and support client needs in drug development and on-patent projects.
Since 2019, PPS has made or committed more than $30 million in capital investments, both in infrastructure and the operations at the Digwal site, in order to improve performance, gain efficiencies, and increase capacity to meet market demands. A focal point of the program is the company's emphasis on operational excellence (OE) as part of the global corporate culture. By applying specific OE tools, including Theory of Constraint, Value Stream Mapping, Optimization of Unit Operations, and Line Balancing, more than 20% of the site's capacity has been released to date. Additional capacity will be released in the coming months as the OE tools generate further benefits.
"We are now seeing the fruits of our labor in applying operational excellence practices at Digwal,” says Peter DeYoung, CEO of PPS. “Coupled with the capital investment we are making, our API capabilities at the site are moving to the next level. Digwal can now take on more complex and larger-scale projects than it could in the past. It's another example of how we continue to invest and grow to serve market demands, and work with our clients to reduce the burden of disease on patients."
In addition to the increased reactor capacity, the Digwal site will benefit from infrastructure upgrades, such as a renovated administration block, a new canteen facility, and quality control lab revamp.